Convention on International Trade in Endangered Species (CITES)
and is protected from exploitation in most countries (https:// doi.org/10. 2305/iucn.uk.2004 .rlts.t4615a11037468.en; http:// www.iucnredlist.org/details/4615/0). However, green turtles are still in danger and susceptible to population decline due to a variety of harmful causes, mainly from marine and ecosystems pollution, loss of territory, human activity, and infectious diseases (Spotila, 2004 ; http://www.fpir.noaa.gov/PRD/prd_green_ sea_turtle.html, https://www.fws.gov/verobeach/MSRPPDFs/ GreenSeaTurtle.pdf, https://www.worldwildlife.org/species/ sea-turtle).
Ceftriaxone (CEF), a third-generation parenteral cephalosporin, is a broad spectrum bactericidal agent active against a wide range of gram-positive (Staphylococcus spp., Streptococcus spp.) and gram-negative bacteria (Escherichia coli, Proteus mirabilis, Pseudomonas aeruginosa, Klebsiella pneumonia, Enterobacter aerogenes, Salmonella spp., Pasteurella spp.) (Albarellos, Kreil, & Landoni, 2007; Lamb, Ormrod, Scott, & Figgitt, 2002; Ringger, Brown, Kohlepp, Growall, & Merrit, 1998; Ringger, Pearson, Gronwell, & Kohlepp, 1996) . The stability against beta-lactamase activity makes this drug a good choice for the treatment of a number of bacterial infections in humans and animals. Due to high potency and wide distribution in most body tissues and fluids, it was approved for use in veterinary medicine for moderate to severe infection in various organ systems including respiratory tract, skin, bone, soft tissues, central nervous system (CNS), and urinary tract (Plumb, 2015) . To date, the pharmacokinetics of CEF have been investigated in many animal species such as pigs (Sumano, del Hevia, Ruiz, Vazquez, & Zamora, 1998) , buffalo calves (Dardi, Sharma, & Srivastav, 2004) , goats (Ismail, 2005) , cats (Albarellos et al., 2007) , dogs (Rebuelto et al., 2002) , camels (Goudah, 2008) , and horses (Ringger et al., 1996) . The pharmacokinetics of two other cephalosporins have been evaluated in other turtle species: ceftazidime in loggerhead sea turtles (Caretta caretta; Stamper et al., 1999) and cefquinome in red-eared sliders (Trachemys scripta elegans; Uney et al., 2018) . However, limited information exists on the pharmacokinetics of antimicrobial drugs in green turtles, even though their use for prophylaxis and treatment of bacterial infection is frequent and necessary. In addition, dosage regimens extrapolated from other species can increase the risk for both toxicity to the animals and therapeutic failure. Consequently, the lack of effective dosing regimens makes designing treatment plans difficult and in the absence of these, substantial direct and indirect mortality in sea turtles results. To achieve the maximum benefits from antimicrobial treatment, accurate information on drug disposition is necessary to allow appropriate decisions on antimicrobial therapy and ultimately to optimize the success of C. mydas conservation plans. The aim of this study was therefore to evaluate the pharmacokinetic characteristics of CEF following a single intravenous and intramuscular administration at a dosage of 10 and 25 mg/kg body weight in green sea turtles. 
| MATERIAL S AND ME THODS

| Animals
| Drugs and chemicals
| Experimental design
Ten green sea turtles were weighed and enrolled in a series of cross over studies. In the first study, the turtles were divided into two groups (n = 5) using randomization software. Each group was admin- 2, 4, 8, 12, 24, 48, 72 , and 96 hr after drug administration. The plasma was separated by centrifugation (1,968 g) for 15 min and immediately stored at −80°C for 2 weeks before analysis. The doses of CEF used in this experiment were based on preliminary and earlier studies on mammal species (Albarellos et al., 2007; Goudah, 2008) . No adverse effects at the point of injection and no behavioral or health alterations were observed in the experimental animals during or after the study.
| Sample extraction procedure
The CEF extraction method was modified from those previously described (Campos et al., 2017; Goudah, 2008) . Briefly, 200 μl of plasma sample was added to 20 μl of IS solution (0.125 μg/ml ENR) in a 2 ml plastic centrifuge tube. Then, 20 μl of glacial acetic acid and 600 μl of cold acetonitrile were added and vortex-mixed for 3 min.
The mixture was centrifuged at 15,500 g for 10 min. The supernatant was collected, passed through 0.22 μm PVDF syringe filter and subjected to liquid chromatography tandem mass spectrometry (LC-MS/MS).
| LC parameters
The LC analysis was performed using an Agilent 1200 series system consisting of a binary high-pressure gradient pump, a vacuum solvent degassing unit, an automatic sample injector, and a column thermostat (Agilent Technologies, Waldbronn, Germany). Separation was achieved using a ZORBAX Eclipse Plus Rapid Resolution HT C18
column (4.6 × 50 mm, 1.8 μm particle size; Agilent Technologies) with guard column (4.6 × 5 mm, 1.8 μm particle size; Agilent Technologies). The column was maintained at a temperature of 35°C. The LC mobile phase program consisted of a binary gradient of 0.2% formic acid in water (mobile phase A) and 0.2% formic acid in acetonitrile (mobile phase B). The gradient condition was as follows:
0-2.0 min, from 90% to 80% A; 2.0-4.5 min, 80% A; 4.5-6.0 min, from 80% to 10% A; 6.0-9.0 min, 10% A; 9.0-9.10 min, from 10%-90%, followed by re-equilibration at 90% A until 13. The flow rate was 300 μl/min, and the injection volume was 5 μl. 
| MS parameters
| Validation procedure
The calibration standard concentrations were prepared by spiking the working standard solution into blank plasma to yield final concentrations of 0.05, 0.1, 0.5, 1, 5, 10, 20, 40, and 80 μg/ml. The r 2 value of the CEF calibration curves was 0.999. Seven duplicates of the quality control sample at concentrations of 0.05, 1, 10, and 20 μg/ml were prepared and used to determine the recoveries, intra-day and inter-day precision, and accuracy of the method. The procedure was repeated five times within the same day to gain intraday run precision and accuracy and five times for each concentration over five different days to obtain inter-day run precision and accuracy. The extraction recoveries were 87.14 ± 5.33%, 90.91 ± 4.74%, 100.18 ± 5.54%, and 99.46 ± 1.39% for 0.05, 1, 10, and 20 μg/ml, respectively. The intra-day precision and accuracy ranged from 2.82% to 8.81% and from 89.18% to 108.20%, respectively. The inter-day precision and accuracy ranged from 5.61% to 7.57% and from 92.69% to 105.17%, respectively. The limit of quantification of CEF was 0.05 μg/ml.
| Plasma protein binding assay
Protein binding was determined by ultracentrifugation (Optima™ Max-XP; Beckman Coulter, Inc, USA) (Craig & Suh, 1980) . CEF free plasma samples from green sea turtles and phosphate buffer saline were added to known concentrations of CEF ranging from 1 to 10 μg/ml. Samples were centrifuged at 480,000 g for 2.30 hr. 
| Pharmacokinetic analysis
The concentration of CEF in the experimental turtles with respect to time was pharmacokinetically analyzed using a noncompartment model (ThothPro™ software). C 0 p was the peak concentration at the initial time, C max was peak plasma concentration, T max was time at peak plasma concentration, AUC 0-inf was the area under the curve from 0 hr to infinity, t 1/2λ was the elimination half-life, V d was the volume of distribution, Cl was the plasma clearance, MRT was the mean residence time, Vd ss was the volume of distribution at steadystate. The i.m. bioavailability (F) was calculated using the following equation:
| Statistical analysis
Pharmacokinetic variables were evaluated using the Student's t test to determine statistically significant differences between groups (10 vs. 25 mg/kg b.w.). Both pharmacokinetic parameters and CEF plasma concentrations are presented as means ± SD (normality tested by Shapiro-Wilk test). All analyses were conducted using GraphPad InStat (GraphPad Software, La Jolla, CA, USA).
Differences were considered significant if p < 0.05. 
| D ISCUSS I ON
The present study was designed to characterize the pharmacokinetic features of CEF after i.v. and i.m. administrations at the dosages of 10 and 25 mg/kg b.w. in green sea turtles, C. mydas. Previously reported pharmacokinetic studies of CEF have been described in several animal species, including camels (Goudah, 2008) , ewes (Goudah, Shin, Shim, & Abd El-Aty, 2006), goats (Ismail, 2005) , sheep (Guerrini, Filippich, & Cao, 1985) , buffalo calves (Dardi, Sharma, & Srivastav, 2005; Dardi et al., 2004) , cattle (Johal & Srivastava, 1998 , calves (Soback & Ziv, 1988) , foals (Ringger et al., 1998) , horses (Ringger et al., 1996) , dogs (Hidefumi, Komiya, Lkeda, & Tachibana, 1984; Rebuelto et al., 2002) , humans (Benet & William, 1991) , rats, and rhesus monkeys (Hidefumi et al., 1984) . However, there is no report on the pharmacokinetics of CEF in sea turtles. Drug dosages in sea turtles are often extrapolated from domestic animals or members of similar taxonomic orders, but even careful allometric scaling based on similar species can result in unpredictable pharmacokinetic profiles and drug toxicoses. In this study, the critical pharmacokinetic Cavalier et al., 1997) . On the other hand, this value was lower than in humans (7.3 hr; Benet & William, 1991 (Stamper et al., 1999; Uney et al., 2018) . Differences in elimination half-life among species are very difficult to evaluate because t 1/2λ is an hybrid parameter that reflects not only elimination but also distribution (Toutain & Bosuet-melou, 2004) . Therefore, the origin of any differences among species on this parameter could be based on differences either on the elimination or distribution processes. The absolute i.m. bioavailability of CEF was 67% ± 5.46% and 108 ± 6.54% at dosages of 10 and 25 mg/ Guerrini et al., 1985) , and calves (0.19 L hr −1 kg −1 ; Soback & Ziv, 1988) . The differences in the pharmacokinetic parameters of CEF in green sea turtles compared to those in animals reared elsewhere and those in other species dictate that the dosage regimen of this antibiotic should be based on a determination of the kinetics taking into account any physiological, anatomical, and metabolism differences in those species (Haddad, Pedersoli, Ravis, Fazeli, & Carson, 1985) . Ceftriaxone is excreted by both renal and non-renal mechanisms in mammals (Plumb, 2018) ; excretory pathways in sea turtles have not been determined.
In the present study, lidocaine was co-administered with CEF. An interaction between the two active ingredients is likely negligible. In studies of lidocaine as a diluent of CEF in humans, none showed any changes in pharmacokinetic parameters of this antibiotic (Schichor et al., 1994) . On the other hand, lidocaine reportedly reduced pain intensity after CEF injection when compared with sterile water as a diluent (Schichor et al., 1994) .
The percentage of protein binding of CEF in green sea turtles' plasma was somewhat moderate, ranging from 20% to 29% with an average of 24.6%. There are different reports on this value in various species including camels (33%-42%, Goudah, 2008) , lactating ewes (29%-37%, Goudah et al., 2006) , lactating goats (39%-45%, Ismail, 2005) , calves (20%-36%, Soback & Ziv, 1988) , and humans (87%-96%, Seddon, Wise, Gillette, & Livingston, 1980). The variation in TA B L E 1 Mean ± SD value of the pharmacokinetic parameters of ceftriaxone following i.v. and i.m. administration at dosages of 10 and 25 mg/kg bw, in green sea turtles (n = 5) : plasma concentration at initial time; F: oral bioavailability; Kel: elimination rate constant; MRT: mean residence time; t 1/2λ : elimination half-life; T max : time at maximum concentration; V d : volume of distribution; V dss : volume of distribution at steady-state. *Significant different from group that received ceftriaxone intravenously at a dosage of 10 mg/kg, p < 0.05. **Significant different from group that received ceftriaxone intramuscularly at a dosage of 10 mg/kg, p < 0.05. protein binding of CEF in different species might be attributed to the presence of two binding sites on serum albumin of humans (a high affinity-low capacity site and a low affinity-high capacity site), whereas only one binding site has been detected in horses (Popick, Crouthamel, & Bekersky, 1987) . The degree of protein binding in human is even higher than that reported for animals.
The minimum inhibitory concentration (MIC) values for CEF are about 0.03-0.2 μg/ml for most susceptible micro-organisms which cause significant disease in animal species consisting of Salmonella, E. coli, and Pasteurella multocida micro-organisms (Soback & Ziv, 1988) . The persistence of antibiotic concentrations in plasma and tissues above the MIC is the pharmacodynamic variable related to the clinical efficacy of CEF (Knudsen, Frimodt-Moller, & Espersen, 1995; Toutain, Del Castillo, & Bousquet-Melou, 2002) . The values of C max after i.m. administration exceeded the recommended susceptibility break-point for CEF of 8 μg/ml (Huang, Carroll, Cosgrove, & Tamma, 2014) by more than 2.1 and 5.1 fold after i.m. administration at dosages of 10 and 25 mg/kg b.w. CEF is a time-dependent antibiotic, and T > MIC is the best PK/PD predictor for its efficacy. In this study, effective plasma concentrations of CEF against Salmonella, E. coli, and P. multocida micro-organisms (MIC90: 0.2 μg/ml) were attained up to 12 and 48 hr after i.m. administration at dosages of 10 and 25 mg/kg b.w., respectively. Nevertheless, the MICs derived in vitro in serum, exudate or transudate was not performed in this study. However, drug efficacy might depend on many factors, including species and strain of micro-organism, pathogenicity, pathogen load, host immune-competence, and drug interaction (Brentnall, Cheng, McKellar, & Lees, 2013) . The MIC values of the important bacterial pathogens that affect sea turtles should be examined for efficacious use of CEF in green sea turtles.
In summary, CEF was detected in plasma of the green sea turtle, C. mydas, after i.m. administration at dosages of 10 and 25 mg/ kg b.w. In this study, the dosage of 10 and 25 mg/kg b.w. produced CEF plasma concentrations higher than 0.2 μg/ml for 12 and 48 hr after i.m. administration, respectively. Therefore, a dosage of 10 and 25 mg/kg b.w following i.m. administration might be appropriate to be effective for 12 and 48 hr, respectively, to treat sensitive pathogenic bacteria in green sea turtles. However, further PK/PD studies are warranted to confirm if the dosage used in this study can produce antimicrobial success for diseases caused by susceptible bacteria in green sea turtles.
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